235 related articles for article (PubMed ID: 18818926)
1. Strontium ranelate decreases plasma homocysteine levels in postmenopausal osteoporotic women.
Bayhan I; Uygur D; Ugurlu N; Ozaksit G
Rheumatol Int; 2009 Jan; 29(3):263-6. PubMed ID: 18818926
[TBL] [Abstract][Full Text] [Related]
2. Strontium ranelate for preventing and treating postmenopausal osteoporosis.
O'Donnell S; Cranney A; Wells GA; Adachi JD; Reginster JY
Cochrane Database Syst Rev; 2006 Jul; (3):CD005326. PubMed ID: 16856092
[TBL] [Abstract][Full Text] [Related]
3. Effects of strontium ranelate on markers of cardiovascular risk in postmenopausal osteoporotic women.
Atteritano M; Catalano A; Santoro D; Lasco A; Benvenga S
Endocrine; 2016 Jul; 53(1):305-12. PubMed ID: 26304851
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of strontium ranelate in the treatment of osteoporosis in men.
Kaufman JM; Audran M; Bianchi G; Braga V; Diaz-Curiel M; Francis RM; Goemaere S; Josse R; Palacios S; Ringe JD; Felsenberg D; Boonen S
J Clin Endocrinol Metab; 2013 Feb; 98(2):592-601. PubMed ID: 23341486
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness of strontium ranelate versus risedronate in the treatment of postmenopausal osteoporotic women aged over 75 years.
Hiligsmann M; Bruyère O; Reginster JY
Bone; 2010 Feb; 46(2):440-6. PubMed ID: 19716940
[TBL] [Abstract][Full Text] [Related]
6. Effects of long-term strontium ranelate treatment on vertebral fracture risk in postmenopausal women with osteoporosis.
Meunier PJ; Roux C; Ortolani S; Diaz-Curiel M; Compston J; Marquis P; Cormier C; Isaia G; Badurski J; Wark JD; Collette J; Reginster JY
Osteoporos Int; 2009 Oct; 20(10):1663-73. PubMed ID: 19153678
[TBL] [Abstract][Full Text] [Related]
7. Effect of strontium ranelate on serum leptin and bone turnover markers in women with established postmenopausal osteoporosis.
Bayhan I; Dogan NU; Ozaksit G; Uygur D; Ugurlu N; Ugur M
J Reprod Med; 2013; 58(7-8):319-23. PubMed ID: 23947082
[TBL] [Abstract][Full Text] [Related]
8. The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis.
Meunier PJ; Roux C; Seeman E; Ortolani S; Badurski JE; Spector TD; Cannata J; Balogh A; Lemmel EM; Pors-Nielsen S; Rizzoli R; Genant HK; Reginster JY
N Engl J Med; 2004 Jan; 350(5):459-68. PubMed ID: 14749454
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of 2 g/day of strontium ranelate in Asian women with postmenopausal osteoporosis.
Liu JM; Wai-Chee Kung A; Pheng CS; Zhu HM; Zhang ZL; Wu YY; Xu L; Meng XW; Huang ML; Chung LP; Hussain NH; Sufian SS; Chen JL
Bone; 2009 Sep; 45(3):460-5. PubMed ID: 19464401
[TBL] [Abstract][Full Text] [Related]
10. Protelos: nonvertebral and hip antifracture efficacy in postmenopausal osteoporosis.
Adami S
Bone; 2006 Feb; 38(2 Suppl 1):23-7. PubMed ID: 16434247
[TBL] [Abstract][Full Text] [Related]
11. Effects of long-term strontium ranelate treatment on the risk of nonvertebral and vertebral fractures in postmenopausal osteoporosis: Results of a five-year, randomized, placebo-controlled trial.
Reginster JY; Felsenberg D; Boonen S; Diez-Perez A; Rizzoli R; Brandi ML; Spector TD; Brixen K; Goemaere S; Cormier C; Balogh A; Delmas PD; Meunier PJ
Arthritis Rheum; 2008 Jun; 58(6):1687-95. PubMed ID: 18512789
[TBL] [Abstract][Full Text] [Related]
12. Strontium ranelate for preventing and treating postmenopausal osteoporosis.
O'Donnell S; Cranney A; Wells GA; Adachi JD; Reginster JY
Cochrane Database Syst Rev; 2006 Oct; 2006(4):CD005326. PubMed ID: 17054253
[TBL] [Abstract][Full Text] [Related]
13. Hip cortical thickness assessment in postmenopausal women with osteoporosis and strontium ranelate effect on hip geometry.
Briot K; Benhamou CL; Roux C
J Clin Densitom; 2012; 15(2):176-85. PubMed ID: 22321661
[TBL] [Abstract][Full Text] [Related]
14. Long-term treatment of postmenopausal osteoporosis with strontium ranelate: results at 8 years.
Reginster JY; Bruyère O; Sawicki A; Roces-Varela A; Fardellone P; Roberts A; Devogelaer JP
Bone; 2009 Dec; 45(6):1059-64. PubMed ID: 19679207
[TBL] [Abstract][Full Text] [Related]
15. Strontium ranelate: vertebral and non-vertebral fracture risk reduction.
Seeman E
Curr Opin Rheumatol; 2006 Jun; 18 Suppl 1():S17-20. PubMed ID: 16735841
[TBL] [Abstract][Full Text] [Related]
16. Strontium ranelate for the management of osteoporosis.
Lam S; Zouzias K
Consult Pharm; 2008 Jul; 23(7):531-7. PubMed ID: 18764671
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of strontium ranelate in combination with a D-hormone analog for the treatment of postmenopausal osteoporosis.
Abboskhujaeva LS; Ismailov SI; Alikhanova NM
Drugs R D; 2014 Dec; 14(4):315-24. PubMed ID: 25480348
[TBL] [Abstract][Full Text] [Related]
18. A meta-analysis of the effect of strontium ranelate on the risk of vertebral and non-vertebral fracture in postmenopausal osteoporosis and the interaction with FRAX(®).
Kanis JA; Johansson H; Oden A; McCloskey EV
Osteoporos Int; 2011 Aug; 22(8):2347-55. PubMed ID: 21287148
[TBL] [Abstract][Full Text] [Related]
19. Vertebral fracture risk reduction with strontium ranelate in women with postmenopausal osteoporosis is independent of baseline risk factors.
Roux C; Reginster JY; Fechtenbaum J; Kolta S; Sawicki A; Tulassay Z; Luisetto G; Padrino JM; Doyle D; Prince R; Fardellone P; Sorensen OH; Meunier PJ
J Bone Miner Res; 2006 Apr; 21(4):536-42. PubMed ID: 16598373
[TBL] [Abstract][Full Text] [Related]
20. The effect of strontium ranelate on serum insulin like growth factor-1 and leptin levels in osteoporotic post-menopausal women: a prospective study.
Gulhan I; Bilgili S; Gunaydin R; Gulhan S; Posaci C
Arch Gynecol Obstet; 2008 Nov; 278(5):437-41. PubMed ID: 18322691
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
